Edaravone administration and its potential association with a new clinical syndrome in cerebral infarction patients:Three case reports  

作　　者：Liu Yang Xin Xu Liang Wang Ke-Bin Zeng Xue-Feng Wang 

机构地区：[1]Department of Neurology,Central Hospital Affiliated to Chongqing University,Chongqing 400010,China [2]Department of Neurology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China

出　　处：《World Journal of Clinical Cases》2023年第19期4648-4654,共7页世界临床病例杂志

摘　　要：BACKGROUND Edaravone is a widely used treatment for patients with cerebral infarction and,in most cases,edaravone-induced side effects are mild.However,edaravone-related adverse reactions have been receiving increasing attention.CASE SUMMARY We treated three patients with acute cerebral infarction who died following treatment with edaravone.Edaravone is a widely used treatment for patients with cerebral infarction and,in most cases,edaravone-induced side effects are mild.However,edaravone-related adverse reactions have been receiving increasing attention.CONCLUSION Our cases highlight the importance of educating clinicians regarding the new edaravone-induced clinical syndromes of cerebral infarction as potentially fatal adverse drug reactions.Considering that no laboratory or confirmatory test exists to diagnose edaravone-induced death from cerebral infarction,clinicians’knowledge is the key element in recognizing this phenomenon.

关 键 词：EDARAVONE Sudden death PATIENTS Cerebral infarction Case report 

分 类 号：R743.33[医药卫生—神经病学与精神病学]